Literature DB >> 28389416

Cell surface GRP78 facilitates hepatoma cells proliferation and migration by activating IGF-IR.

Yancun Yin1, Chen Chen2, Jinliang Chen2, Renhui Zhan2, Qiang Zhang3, Xiaoyan Xu3, Defang Li4, Minjing Li5.   

Abstract

The 78kDa glucose regulated protein (GRP78) is a multifunctional chaperone that is involved in a variety of cellular processes. Insulin like growth factor I receptor (IGF-IR) often aberrant expresses in many types of tumor cells. The IGF-IR signaling plays key roles in carcinogenesis and maintenance of the malignant phenotype. The crosstalk between GRP78 and IGF-IR molecules has not well been illuminated. Here, we demonstrated a reciprocal regulation of GRP78 expression and IGF-IR pathway activation. IGF-I induced GRP78 expression in hepatoma cells. IGF-IR knockdown or IGF-IR inhibitor repressed GRP78 expression. Both phosphatidylinositol 3-kianase (PI3K) and mitogen-activated protein kinase (MAPK) pathways involved in IGF-I induction of GRP78 expression. Interestingly, treatment of hepatoma cells with IGF-I re-distributes GRP78 from endoplasmic reticulum (ER) to cell surface and promotes its physical interaction with IGF-IR. Also, GRP78 promotes IGF-IR phosphorylation and activation. Blocked of GRP78 by small interfering RNA or inhibition of GRP78 function by (-)-epigallocatechin gallate (EGCG) blocks IGF-I induced IGF-IR phosphorylation and its downstream signaling. Further, blocked cell surface GRP78 with antibody inhibits IGF-I stimulated cellular proliferation and migration. These data reveal an essential role for the molecular chaperone GRP78 in IGF-IR signaling and implicate the use of GRP78 inhibitors in blocking IGF-IR signaling in hepatoma cells.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GRP78; Hepatoma; IGF-IR; Signaling

Mesh:

Substances:

Year:  2017        PMID: 28389416     DOI: 10.1016/j.cellsig.2017.04.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  7 in total

1.  GRP78 facilitates M2 macrophage polarization and tumour progression.

Authors:  Heng Zhang; Shao-Qiang Wang; Lin Hang; Chun-Fang Zhang; Li Wang; Chao-Jun Duan; Yuan-Da Cheng; Dong-Kai Wu; Ri Chen
Journal:  Cell Mol Life Sci       Date:  2021-10-28       Impact factor: 9.261

2.  The interaction between SPARC and GRP78 interferes with ER stress signaling and potentiates apoptosis via PERK/eIF2α and IRE1α/XBP-1 in colorectal cancer.

Authors:  Yi-Jye Chern; John C T Wong; Grace S W Cheng; Angel Yu; Yaling Yin; David F Schaeffer; Hagen F Kennecke; Gregg Morin; Isabella T Tai
Journal:  Cell Death Dis       Date:  2019-06-26       Impact factor: 8.469

Review 3.  The Insulin Receptor: An Important Target for the Development of Novel Medicines and Pesticides.

Authors:  Xiaohong Zhang; Xuezhen Zhu; Xiaoyang Bi; Jiguang Huang; Lijuan Zhou
Journal:  Int J Mol Sci       Date:  2022-07-14       Impact factor: 6.208

4.  EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress.

Authors:  Wenbing Wu; Hui Gou; Bin Xiang; Ruiman Geng; Jingying Dong; Xiaolong Yang; Dan Chen; Rongyang Dai; Lihong Chen; Ji Liu
Journal:  J Oncol       Date:  2022-09-13       Impact factor: 4.501

5.  Galectin‑1 binds GRP78 to promote the proliferation and metastasis of gastric cancer.

Authors:  Qi Zhang; Muhammad Ali; Yang Wang; Qian-Nan Sun; Xiao-Dong Zhu; Dong Tang; Wei Wang; Cang-Yuan Zhang; Hai-Hua Zhou; Dao-Rong Wang
Journal:  Int J Oncol       Date:  2022-09-30       Impact factor: 5.884

6.  Targeting oral cancer stemness and chemoresistance by isoliquiritigenin-mediated GRP78 regulation.

Authors:  Fang-Wei Hu; Cheng-Chia Yu; Pei-Ling Hsieh; Yi-Wen Liao; Ming-Yi Lu; Pei-Ming Chu
Journal:  Oncotarget       Date:  2017-09-28

7.  GRP78-Mediated Signaling Contributes to Axonal Growth Resulting in Motor Function Recovery in Spinal Cord-Injured Mice.

Authors:  Yoshitaka Tanie; Tomoharu Kuboyama; Chihiro Tohda
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.